4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosusRecruitingPhase 32026-10-01NCT06133972
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)Skin and Connective Tissue Diseases, connective tissue disorder, muscle tissue disorder, musculoskeletal system disorder, polymyalgia rheumatica, rheumatic disorderActive, not recruitingPhase 32026-08-21NCT06331312
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosusActive, not recruitingPhase 32026-08-21NCT05639114
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseSkin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, systemic lupus erythematosusActive, not recruitingPhase 22026-06-05NCT06293365